According to the findings of the Russian analytical company DSM Group, the demand for weight loss drugs in Russia has been steadily surging since the beginning of 2023. Sales increased by 20.3% in terms of quantity, which accounted for a remarkable 1.5 million packs. In terms of monetary value, the increase amounted to 15.5%, equivalent to 4.2 billion rubles compared to the previous year.
Sibutramine-containing products such as “Reduxin” and “Goldline” are the top choices for most Russians, with 44% and 33% of the total market share respectively. Listata, Orsoten, Xenical, and Xenalten (orlistat) are relatively uncommonly sold. Over 99% of sales come from pharmacies.
